The October 2020 summary of P&R decisions in Spain is now available for downloading
The October 2020 summary of P&R decisions from the Spanish Interministerial [...]
Chronic liver disease-associated severe thrombocytopenia in Spain through Delphi method
Management of chronic liver disease-associated severe thrombocytopenia in Spain: [...]
The June 2020 summary of P&R decisions in Spain is now available for downloading
The June 2020 summary of P&R decisions from the Spanish Interministerial Med [...]
Analysis of Orphan Drugs P&R criteria in Spain (2003-2019)
Impact of the therapeutic positioning report in the P&R process in Spain: an [...]
Omakase Lab – Horizon Scanning of Oncological Medications
In this report, Omakase Consulting, in collaboration with the ECO Institution, h [...]
Acute myeloid leukaemia in Spain through Delphi method
Current status of acute myeloid leukaemia in Spain: Results from a Delphi study [...]
Burden of Carbapenem-Resistant Gram-Negative Infections in Spain
Determining the burden of infectious diseases caused by carbapenem-resistant gra [...]
MCDA Hemlibra® in haemophilia A without inhibitors
Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis [...]
MCDA inhaler device in COPD treatment
Is patients’ perspective incorporated when choosing an inhaler device for COPD t [...]
MCDA framework for Oncologic Treatments
Development of a Multicriteria Decision Analysis Framework for Evaluating and Po [...]